| Literature DB >> 34942962 |
Muthu Thiruvengadam1, Baskar Venkidasamy2, Umadevi Subramanian3, Ramkumar Samynathan4, Mohammad Ali Shariati5,6, Maksim Rebezov6,7, Shabari Girish8, Sivakumar Thangavel9, Anand Raj Dhanapal10, Natalya Fedoseeva11, Joohyun Lee1, Ill-Min Chung1.
Abstract
Oxidative stress is a pathological condition occurring due to an imbalance between the oxidants and antioxidant defense systems in the body. Nuclear factor E2-related factor 2 (NRF2), encoded by the gene NFE2L2, is the master regulator of phase II antioxidant enzymes that protect against oxidative stress and inflammation. NRF2/ARE signaling has been considered as a promising target against oxidative stress-mediated diseases like diabetes, fibrosis, neurotoxicity, and cancer. The consumption of dietary phytochemicals acts as an effective modulator of NRF2/ARE in various acute and chronic diseases. In the present review, we discussed the role of NRF2 in diabetes, Alzheimer's disease (AD), Parkinson's disease (PD), cancer, and atherosclerosis. Additionally, we discussed the phytochemicals like curcumin, quercetin, resveratrol, epigallocatechin gallate, apigenin, sulforaphane, and ursolic acid that have effectively modified NRF2 signaling and prevented various diseases in both in vitro and in vivo models. Based on the literature, it is clear that dietary phytochemicals can prevent diseases by (1) blocking oxidative stress-inhibiting inflammatory mediators through inhibiting Keap1 or activating Nrf2 expression and its downstream targets in the nucleus, including HO-1, SOD, and CAT; (2) regulating NRF2 signaling by various kinases like GSK3beta, PI3/AKT, and MAPK; and (3) modifying epigenetic modulation, such as methylation, at the NRF2 promoter region; however, further investigation into other upstream signaling molecules like NRF2 and the effect of phytochemicals on them still need to be investigated in the near future.Entities:
Keywords: NRF2; cancer; diabetes; epigenetic modification; oxidative stress; phytochemicals
Year: 2021 PMID: 34942962 PMCID: PMC8698417 DOI: 10.3390/antiox10121859
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1NRF2 activation and nuclear translocation. Cullin3 (Cul3), ring box protein-1 (RBX1), antioxidant response elements (AREs), and the endoplasmic reticulum (ER).
Figure 2NRF2 signaling pathway is linked with several diseases.
Figure 3The effects of bioactive compounds in the activation of NRF2 pathways for cancer prevention.
Figure 4Phytochemicals target NRF2 to inhibit cancer, diabetes, neurotoxicity, cardiac disease, and kidney injury.
Figure 5Chemical structure of the bioactive compounds.
Phytochemicals that target the NRF2-signaling pathway in various diseases.
| S.No | Phytochemicals | Molecular Target | Cell/Animal Model | Function | Refs |
|---|---|---|---|---|---|
| 1. | Luteolin | p62/KEAP1/NRF2 | Adult male Sprague−Dawley rats | Neuroprotection | [ |
| 2. | Fucoxanthin | NRF2 signaling pathway | Skin JB6 P+ cells | Anticancer effect | [ |
| 3. | Corosolic acid | Swiss albino mice | Antidiabetic | [ | |
| 4. | Reserpine | Epigenetic modulation of | Skin epidermal JB6 P+ cells | Anticancer | [ |
| 5. | Taxifolin | NRF2 signaling pathway | Male Swiss Albino Mice | Antioxidant and anti-inflammatory | [ |
| 6. | Ganoderic acid | Lung cancer H460 cells | Anticancer | [ | |
| 7. | Celastrol | Male Wistar albino rat | Antifibrotic | [ | |
| 8. | Polydatin | miR-200a to control KEAP1/NRF2 pathway b | BRL-3A cells | anti-inflammatory and antihyperlipidemic | [ |
| 9. | Pelargonidin | NRF2 promoter demethylation | Skin epidermal JB6 P+ cells. | Anticancer | [ |
| 10. | Delphinidin | Epigenetic reactivation of NRF2 | Skin epidermal JB6 P+ cells. | Anticancer | [ |
List of compounds that act as activators and inhibitors of the NRF2-signaling pathway.
| S. No | Compounds | Activator/Inhibitor | Cell/Animal Model/ | Mechanism | Refs |
|---|---|---|---|---|---|
| 1. | Ursodiol | FDA approved drug acting as NRF2 activator | KEAP1- knockdown mice, | Activate NRF2; induces of Mrp family members in livers, stimulates detoxification and antioxidative stress systems | [ |
| 2. | Dimeric acid | NRF2 activator | Balb/C mice | Activates NRF2, increases hepatic glyoxalase and glutathione, reduces serum and hepatic AGE levels and suppresses inflammatory in MG induced diabetic mice | [ |
| 3. | Songorine | NRF2 activator | C57BL/6 mice | Activates NRF2/ARE signaling cascades to rescue cardiomyocytes from endotoxin insult and prevents septic heart injury | [ |
| 4. | Procyanidins | NRF2 inhibitor | A549 cells | Promotes proteasome-independent degradation of nuclear NRF2 via phosphorylating IGF-1 receptor and activating cysteine proteases | [ |
| 5. | Compound KI-696 | KEAP1 Kelch–NRF2 interactions inhibitor | NHBE cells, Bronchial epithelial cells from human COPD patient lung | [ | |
| 6. | Cyclic peptide head to tail | KEAP1–NRF2-specific protein inhibitor | Mouse RAW 264.7 cells; HepG2-ARE-C8 cells. | Upregulates NRF2-dependent antioxidant proteins and enzymesenhance the antioxidant capacity and inhibit inflammation factors in LPS-induced macrophage RAW 264.7 cells | [ |
| 7. | Coumarins | Inhibits KEAP1/NRF2 protein–protein interactions | Molecular docking simulation studies | Binds with Keap and activate NRF2 signaling | [ |
| 8. | Napyradiomycin (Compound | potent NRF2 activator | BV-2 microglial cells | Exhibits antioxidant and anti-inflammatory effects | [ |
| 9. | ML385 | NRF2 inhibitor | Tumor xenograft mice | Improves chemotherapeutic efficacy by interacting with NRF2 and inhibiting its transcriptional activity | [ |
| 10. | Trigonelline | NRF2 inhibitor | Head and neck cancer cells (HN3R) | Inhibition of the NRF2-ARE mechanism reverses ferroptosis resistance in HNSCC cells | [ |
List of phytochemicals modulating the epigenetic changes involved in pathological conditions.
| S. No | Phytochemicals | Epigenetic Modification and Mechanism | Cell/Animal Model | Function | Refs |
|---|---|---|---|---|---|
| 1. | Naringenin | Histone acetylation-dependent inhibition of thioredoxin-interacting protein expression; | diabetic db/db mouse and INS-1 pancreatic β cell line | Protects pancreatic beta cells and inhibit the progression of type II diabetes | [ |
| 2. | Pterostilbene | Apoptosis in cancer cells is regulated by theMTA1/HDAC1/NuRD complex | SMMC-7721 | suppressed the growth, and invasion of hepatocellular carcinoma | [ |
| 3. | 3,4-dihydroxytoluene, a rutin metabolite | Inhibited p300 histone acetyltransferase activity and induced hypoacetylation at H3K9, H3K36, H4K8 and H4K16. | HepG2 cells ob/ob mice | Suppressed the progression of nonalcoholic fatty liver disease | [ |
| 4. | Cinnamaldehyde | Regulates PERK-CHOP signaling, Inhibits G9a histone methyltransferase, Mediates autophagic cell death | Gastric cancer cells | Induced autophagy-mediated cell death through ER stress and enhanced epigenetic modification in gastric cancer cells | [ |
| 5. | Xanthohumol | Increased the expression | Marc-145 cells. | Reduces PRRSV-induced oxidative stress and inhibits PRRSV growth | [ |
| 6. | Ganoderic acid | Increased expression of | Senescent human amniotic mesenchymal stem cell | Acts as an anti-aging agent | [ |
| 7. | Celastrol | Deregulation of various miRNA | Hepatocellular carcinoma | Inhibits the progression of hepatocellular carcinoma | [ |
| 8. | Polydatin | Increases miR200a expression and regulates KEAP1/NRF2 signaling pathway | HepG2 and BRL-3A cells | Reduces fructose-induced liver inflammation and lipid accumulation | [ |
| 9. | Pelargonidin | inhibits DNA recognition and catalytic binding by DNMT1 and DNMT3A | HT29 cells | Regulates cell cycle and inhibits proliferation of colorectal carcinoma cells | [ |
| 10. | Delphinidin | Modulate protein expression of DNMT1, DNMT3a, and class I/II HDACs activates the NRF2-ARE pathway | Mouse epidermal JB6 P+ cells | Inhibits neoplastic transformation and acts as an effective skin cancer chemo preventive agent | [ |
| 11. | Luteolin | regulates NRF2/ARE pathway via modulating DNMTs and HDACs | Human colon cancer cells HCT116 | Exerts anti-tumor activity by blocking cell transformation | [ |
| 12. | Fucoxanthin | Activated NRF2 signaling and reduced DNMT activity | Mouse skin epidermal JB6 P+ cells | Involves in skin cancer prevention and inhibits cell transformation | [ |
| 13. | Corosolic acid | Modules global CpG methylation at tumor promoter | Mouse epidermal JB6 P+ cells | Acts as an effective agent against skin cancer | [ |